BioLife Solutions (NASDAQ:BLFS) Price Target Raised to $31.00

BioLife Solutions (NASDAQ:BLFS) had its target price hoisted by TD Cowen from $28.00 to $31.00 in a research report report published on Wednesday,Benzinga reports. TD Cowen currently has a buy rating on the medical equipment provider’s stock.

A number of other brokerages have also recently commented on BLFS. Northland Securities raised their target price on BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, August 9th. HC Wainwright assumed coverage on shares of BioLife Solutions in a research note on Monday, September 30th. They issued a “buy” rating and a $29.00 price objective for the company. Finally, Craig Hallum upped their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $27.83.

BioLife Solutions Trading Down 2.9 %

BLFS opened at $21.02 on Wednesday. BioLife Solutions has a 52 week low of $11.40 and a 52 week high of $28.88. The company has a quick ratio of 1.81, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $24.00 and a 200-day simple moving average of $22.75. The firm has a market cap of $975.12 million, a P/E ratio of -19.83 and a beta of 1.88.

Insider Buying and Selling

In other BioLife Solutions news, EVP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $23.28, for a total transaction of $232,800.00. Following the completion of the transaction, the executive vice president now owns 317,716 shares in the company, valued at $7,396,428.48. The trade was a 3.05 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CRO Garrie Richardson sold 3,070 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the transaction, the executive now owns 114,773 shares of the company’s stock, valued at $2,883,097.76. This trade represents a 2.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,471 shares of company stock valued at $656,330 in the last ninety days. Company insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BLFS. Mark Sheptoff Financial Planning LLC acquired a new position in BioLife Solutions during the 3rd quarter worth approximately $28,000. 1620 Investment Advisors Inc. acquired a new position in shares of BioLife Solutions in the 2nd quarter valued at $35,000. Isthmus Partners LLC boosted its holdings in shares of BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 42,265 shares in the last quarter. Quest Partners LLC acquired a new position in shares of BioLife Solutions in the 3rd quarter valued at $57,000. Finally, GAMMA Investing LLC boosted its holdings in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.